tak-659
Small moleculeexperimental
Clinical trial activity
15 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2013 (NCT02000934)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Esophageal Neoplasms · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Mutation · Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
- Tyrosine-protein kinase SYKINHIBITOR
SYK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1- Mol. weight
- 344.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3979920 ↗
- ChEMBLCHEMBL3544931 ↗
Also known as
- tak-659
- tak-659
- tak-659
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05319028 | Phase 2 | Jun 23, 2022 | Calithera Biosciences |
| NCT04079738 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Big Ten Cancer Research Consortium, Indiana University, Takeda |
| NCT03772288 | Phase 1 | Apr 3, 2019 | Millennium Pharmaceuticals, Nektar Therapeutics |
| NCT03742258 | Phase 1 | Mar 13, 2019 | National Cancer Institute (NCI), Northwestern University |
| NCT03756818 | Phase 1 | Mar 5, 2019 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03338881 | Phase 1 | May 10, 2018 | Millennium Pharmaceuticals |
| NCT03359733 | Phase 1 | Feb 28, 2018 | Millennium Pharmaceuticals |
| NCT03357627 | Phase 1 | Feb 16, 2018 | Millennium Pharmaceuticals |
| NCT03238651 | Phase 1 | Aug 1, 2017 | Millennium Pharmaceuticals |
| NCT03123393 | Phase 2 | Jun 26, 2017 | Millennium Pharmaceuticals |
| NCT02954406 | Phase 1 | Apr 10, 2017 | Millennium Pharmaceuticals |
| NCT02834247 | Phase 1 | Jul 30, 2016 | Millennium Pharmaceuticals |
| NCT02551055 | Phase 1 | Sep 1, 2015 | Millennium Pharmaceuticals, Takeda |
| NCT02323113 | Phase 1 | Feb 19, 2015 | Millennium Pharmaceuticals |
| NCT02000934 | Phase 1 | Dec 31, 2013 | Millennium Pharmaceuticals |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals | For profit | 11 | 11 | 2 | 2013 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2019 |
| Takeda | For profit | 2 | 0 | 2 | 2015 |
| Big Ten Cancer Research Consortium | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Calithera Biosciences | For profit | 1 | 1 | 1 | 2022 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Nektar Therapeutics | For profit | 1 | 0 | 1 | 2019 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
9 organizations
Page 1 / 1